Literature DB >> 23690262

Atrial fibrillation in heart failure: drug therapies for rate and rhythm control.

Rafik Tadros1, Paul Khairy, Jean L Rouleau, Mario Talajic, Peter G Guerra, Denis Roy.   

Abstract

Pharmacological treatment of atrial fibrillation in the context of heart failure poses numerous challenges. Management decisions are limited by contraindications to several drugs and the paucity of robust clinical trials that provide evidence-based guidance. This review proposes a structured action plan for managing atrial fibrillation coexisting with heart failure that considers published clinical guidelines and integrates recent data derived from substudies of randomized trials, including the atrial fibrillation and congestive heart failure (AF-CHF) trial. Areas of uncertainty, such as target heart rates in atrial fibrillation and upstream therapies, are also discussed.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 23690262     DOI： 10.1007/s10741-013-9395-6

Source DB:  PubMed          Journal:  Heart Fail Rev        ISSN： 1382-4147            Impact factor:   4.214


  81 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

2.  Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study.

Authors:  Karl Swedberg; Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Harry Shi; John Vincent; Bertram Pitt
Journal:  J Am Coll Cardiol       Date:  2012-05-01       Impact factor: 24.094

3.  Effect of spironolactone on patients with atrial fibrillation and structural heart disease.

Authors:  Ryan S Williams; James A deLemos; Vassilis Dimas; Joan Reisch; Joseph A Hill; R Haris Naseem
Journal:  Clin Cardiol       Date:  2011-06-14       Impact factor: 2.882

Review 4.  Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events.

Authors:  Dariush Mozaffarian; Jason H Y Wu
Journal:  J Am Coll Cardiol       Date:  2011-11-08       Impact factor: 24.094

5.  Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators.

Authors: 
Journal:  Lancet       Date:  1997-11-15       Impact factor: 79.321

6.  Clinical effects of digoxin on sinus node and atrioventricular node function after pharmacologic autonomic blockade.

Authors:  P Alboni; N Shantha; L Filippi; R Pirani; S Preziosi; A M Tomasi; A Masoni
Journal:  Am Heart J       Date:  1984-11       Impact factor: 4.749

7.  Impact of the β1-adrenoceptor Arg389Gly polymorphism on heart-rate responses to bisoprolol and carvedilol in heart-failure patients.

Authors:  T Rau; H-D Düngen; F Edelmann; F Waagstein; M Lainščak; S Dimković; S Apostolović; A N Nešković; W Haverkamp; G Gelbrich; T Eschenhagen
Journal:  Clin Pharmacol Ther       Date:  2012-05-23       Impact factor: 6.875

8.  Effect of nebivolol on outcome in elderly patients with heart failure and atrial fibrillation: insights from SENIORS.

Authors:  Bart A Mulder; Dirk J van Veldhuisen; Harry J G M Crijns; Michael Böhm; Alain Cohen-Solal; Daphne Babalis; Michael Roughton; Marcus D Flather; Andrew J S Coats; Isabelle C Van Gelder
Journal:  Eur J Heart Fail       Date:  2012-07-04       Impact factor: 15.534

9.  Amiodarone versus sotalol for atrial fibrillation.

Authors:  Bramah N Singh; Steven N Singh; Domenic J Reda; X Charlene Tang; Becky Lopez; Crystal L Harris; Ross D Fletcher; Satish C Sharma; J Edwin Atwood; Alan K Jacobson; H Daniel Lewis; Dennis W Raisch; Michael D Ezekowitz
Journal:  N Engl J Med       Date:  2005-05-05       Impact factor: 91.245

10.  Is beta-blockade useful in heart failure patients with atrial fibrillation? An analysis of data from two previously completed prospective trials.

Authors:  Jeffrey W H Fung; Skiva K W Chan; Leata Y C Yeung; John E Sanderson
Journal:  Eur J Heart Fail       Date:  2002-08       Impact factor: 15.534
View more
  3 in total

Review 1.  Should His Bundle Pacing Be Preferred over Cardiac Resynchronization Therapy Following Atrioventricular Junction Ablation?

Authors:  Zak Loring; Albert Y Sun
Journal:  Cardiol Clin       Date:  2019-02-10       Impact factor: 2.213

Review 2.  Pharmacologic Rate versus Rhythm Control for Atrial Fibrillation in Heart Failure Patients.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Virginia Mplani; Maria Anastasopoulou; Nicholas Kounis; Cesare de Gregorio; Grigorios Tsigkas; Arun Karunakaran; Panagiotis Plotas; Ignatios Ikonomidis
Journal:  Medicina (Kaunas)       Date:  2022-05-30       Impact factor: 2.948

Review 3.  Comorbidity of atrial fibrillation and heart failure.

Authors:  Liang-Han Ling; Peter M Kistler; Jonathan M Kalman; Richard J Schilling; Ross J Hunter
Journal:  Nat Rev Cardiol       Date:  2015-12-10       Impact factor: 32.419
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.